Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025)

Key Points

• This study aims to evaluate the safety and clinical activity of pembrolizumab combined with olaparib in patients with recurrent cervical cancer after platinum-based chemotherapy.
• Conducted a Phase II clinical trial
• Administered pembrolizumab and olaparib to patients
• Monitored safety and clinical activity
• Combination therapy exhibited an acceptable safety profile
• Limited additional clinical activity observed
• Need for appropriate biomarkers identified for effective treatment